Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:AEX NASDAQ:PHAR CVE:ZEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$12.28-2.5%$14.83$9.54▼$21.34$889.17M-0.0411,960 shs3,864 shsZENZentekC$0.63-3.1%C$0.79C$0.56▼C$2.06C$67.75M0.524523126,518 shs155,653 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group-1.64%+2.52%-3.00%-20.72%+6.60%ZENZentek-4.41%-13.33%-35.64%-23.53%-67.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$12.28-2.5%$14.83$9.54▼$21.34$889.17M-0.0411,960 shs3,864 shsZENZentekC$0.63-3.1%C$0.79C$0.56▼C$2.06C$67.75M0.524523126,518 shs155,653 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group-1.64%+2.52%-3.00%-20.72%+6.60%ZENZentek-4.41%-13.33%-35.64%-23.53%-67.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEXAEX Gold 0.00N/AN/AN/APHARPharming Group 2.40Hold$38.33213.69% UpsideZENZentek 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZEN, SAVE, PHAR, and AEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.003/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/13/2026PHARPharming Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$42.00 ➝ $41.003/12/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$37.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEXAEX GoldN/AN/AC$0.13 per share4.59C$0.21 per shareN/APHARPharming Group$376.13M2.29$0.19 per share63.82$3.95 per share3.09ZENZentekC$942.88K73.00C$0.05 per share13.85C$0.12 per share5.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEXAEX GoldN/A-C$0.14N/AN/AN/AN/AN/AN/AN/APHARPharming Group$2.85M$0.1676.3818.80N/A3.30%4.64%2.55%7/30/2026 (Estimated)ZENZentek-C$10.75M-C$0.08N/AN/AN/A-857.10%-61.26%-27.09%N/ALatest ZEN, SAVE, PHAR, and AEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEXAEX GoldN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AZENZentekN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEXAEX Gold2.0919.9019.77PHARPharming Group0.352.632.06ZENZentek15.411.007.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEXAEX GoldN/APHARPharming Group0.03%ZENZentek0.04%Insider OwnershipCompanyInsider OwnershipAEXAEX GoldN/APHARPharming Group2.07%ZENZentek6.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEXAEX GoldN/A177.10 millionN/ANot OptionablePHARPharming Group28070.62 million69.16 millionNot OptionableZENZentek24107.54 millionN/ANot OptionableZEN, SAVE, PHAR, and AEX HeadlinesRecent News About These CompaniesOff-market insider buying at Zentek (ZEN)June 6, 2026 | theglobeandmail.comZentek (CVE:ZEN) Shares Cross Below 200 Day Moving Average - Should You Sell?May 30, 2026 | americanbankingnews.comZentek Raises C$18 Million in Brokered LIFE Financing to Advance Albany Graphite and ZenGUARDMay 27, 2026 | tipranks.comZendesk Appoints Tifenn Dano Kwan as Chief Marketing OfficerMay 27, 2026 | businesswire.comZendesk Commits $100M to Help Startups Build with AI, Expands VC ProgramMay 20, 2026 | businesswire.comZendesk Introduces the Autonomous Service Workforce, Defining the Future of Customer and Employee ServiceMay 19, 2026 | businesswire.comZentek Wins Exclusive Three-Year Federal Pathway for ZenGUARD Graphene Air FiltersMay 13, 2026 | tipranks.comZentek Wins Health Canada Clearance and Opens Canadian Orders for ZenGUARD Air FiltersMay 6, 2026 | tipranks.comZentek Taps ICP Securities for Algorithmic Market-Making to Boost LiquidityApril 1, 2026 | tipranks.comZentek Wins Favorable Court Ruling, Clearing $6 Million in ClaimsMarch 13, 2026 | tipranks.comAmid a defence boom, Zentek takes a fresh look at its Hearst-area graphite depositMarch 10, 2026 | sudbury.comSZentek Ltd.: Zentek Outlines Government Engagement Strategy and Announces Plans to Advance Albany Graphite Toward New Preliminary Economic AssessmentFebruary 26, 2026 | finanznachrichten.deZentek Unveils Strategic Reset, Concentrates on Three Core PlatformsJanuary 29, 2026 | tipranks.comZentek’s Albany graphite achieves nuclear-grade performance, targeting high-value specialty marketsJanuary 6, 2026 | msn.comZentek (CVE:ZEN) Director Mohammed Jiwan Purchases 11,000 Shares of StockJanuary 1, 2026 | insidertrades.comZentek’s Albany Graphite Achieves Breakthrough Lithium-Ion Battery PerformanceDecember 17, 2025 | tipranks.comZentek appoints Mohammed Jiwan CEONovember 25, 2025 | msn.comZentek Ltd.: Zentek Announces Appointment of Mohammed Jiwan as Chief Executive OfficerNovember 25, 2025 | finanznachrichten.deZentek Appoints Mohammed Jiwan as CEO to Drive GrowthNovember 25, 2025 | tipranks.comZentek Faces CRA Reassessment on 2019 Flow-Through FinancingsNovember 21, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?By Jessica Mitacek | May 12, 2026Investors Abandoned These 3 AI Stocks Too Early, Says Jeff ClarkBy Bridget Bennett | May 21, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026ZEN, SAVE, PHAR, and AEX Company DescriptionsAEX Gold CVE:AEXC$0.62 -0.01 (-1.59%) As of 07/11/2022AEX Gold Inc. engages in the acquisition, exploration, and development of mineral properties in Greenland. It holds interests in licenses covering an area of 7,615.85 square kilometers located in South Greenland. The company was formerly known as Alopex Gold Inc. and changed its name to AEX Gold Inc. in June 2018. AEX Gold Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.Pharming Group NASDAQ:PHAR$12.28 -0.31 (-2.46%) Closing price 04:00 PM EasternExtended Trading$12.25 -0.03 (-0.25%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Zentek CVE:ZENC$0.63 -0.02 (-3.08%) As of 03:59 PM EasternZentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
